Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05412394 · ClinicalTrials.gov registry record · Phase 4
Once Weekly Infant Corticosteroid Trial for DMD
A Phase 4 study of Duchenne Muscular Dystrophy, sponsored by Anne M. Connolly.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 4
- Study locations
NCT05412394 is a Phase 4 study of Duchenne Muscular Dystrophy that is actively recruiting participants, run by Anne M. Connolly. The registered enrollment target is 26 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05412394, a Phase 4 study of Duchenne Muscular Dystrophy, is actively recruiting participants, sponsored by Anne M. Connolly.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 4
- Study locations
Study Summary
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
Conditions Studied
Interventions
- DRUG Prednisolone
Study Locations (4)
Ohio
- University of Cincinnati - Cincinnati
- Nationwide Children's Hospital - Columbus
Illinois
- Lurie Children's Hospital of Chicago - Chicago
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05412394
The ClinicalTrials.gov registry entry for NCT05412394 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (94% lower). The listed sponsor is Anne M. Connolly, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Prednisolone is the first listed.
NCT05412394 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT05412394 about?
NCT05412394 is a clinical study titled "Once Weekly Infant Corticosteroid Trial for DMD". The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
What is the current status of trial NCT05412394?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2021-04-30. Estimated completion is 2026-12.
What conditions does trial NCT05412394 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT05412394?
The interventions under investigation include: Prednisolone (DRUG).
Who is sponsoring clinical trial NCT05412394?
This trial is sponsored by Anne M. Connolly, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05412394 being conducted?
This trial has 4 study locations across Illinois, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
ACTIVE NOT RECRUITING · Phase 4
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
The Duchenne Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.